课题基金 / 基金详情

p53-mediated metabolic regulation in tumor suppression

p53-mediated metabolic regulation in tumor suppression
p53介导的肿瘤抑制代谢调节
批准号:
10663249
负责人:
Wei Gu
金额:
$95.26万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2028-08-31

项目摘要

项目成果

Wei Gu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Inactivation of the p53 tumor suppressor is a pivotal event in the formation of most human cancers. p53 acts as a transcription factor to modulate various types of cellular processes to suppress cancer development. Although the classic activities of p53 including cell-cycle arrest, senescence and apoptosis serve as critical barriers to cancer development, accumulating evidence suggests that other unconventional mechanisms such as metabolic regulation are also critically involved in suppressing tumor growth. Nevertheless, despite the fact that the role of the p53 pathway in tumor suppression is indisputable, it remains a daunting task how to target this pathway for cancer therapy. The main issue is whether activation of p53 function in vivo leads to significant tumor regression without causing serious toxicity in normal tissues. Cancer cells rewire cellular metabolism to meet the energetic and substrate demands of tumor development, but this rewiring also creates metabolic vulnerabilities specific for cancer cells. By taking advantage of these metabolic vulnerabilities, our preliminary studies showed that specific activation of the tumor suppression function of p53 through certain metabolic targets can be effective in suppressing tumor growth but apparently does not cause severe harm to normal tissues. The central objective of the proposed research plan is to comprehensively define p53-mediated metabolic regulation program that is required for its tumor suppression as a mean to identify new targets/pathways for therapy. Toward this end, our research program will be based on two complementary lines of research aiming to the further dissection of: 1) p53-mediated metabolic pathways required for its tumor suppression; 2) the novel ferroptosis pathway regulated by p53 and the effects in both normal and cancer cells. We expect that the research program described above will identify specific targets to suppress tumor growth but have minimal or at least manageable toxicity in normal tissues.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41388-022-02331-9
发表时间: 2022-05
期刊: ONCOGENE
影响因子: 8
作者: [Xia, Zhangchuan, Kon, Ning, Gu, Alyssa P., Tavana, Omid, Gu, Wei]
通讯作者: Gu, Wei
DOI: 10.18632/oncoscience.534
发表时间: 2021
期刊: Oncoscience
影响因子: --
作者: [Kon N, Gu W]
通讯作者: Gu W
DOI: 10.1126/sciadv.abi6684
发表时间: 2021-10-29
期刊: Science advances
影响因子: 13.6
作者: [Yang X, Wang X, Li Z, Duan S, Li H, Jin J, Zhang Z, Gu W]
通讯作者: Gu W
DOI: 10.1038/s41467-023-37617-3
发表时间: 2023-04-06
期刊: NATURE COMMUNICATIONS
影响因子: 16.6
作者: [Yi, Jingjie, Tavana, Omid, Li, Huan, Wang, Donglai, Baer, Richard J., Gu, Wei]
通讯作者: Gu, Wei
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
p53-mediated metabolic regulation in tumor suppression
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
海外基金